Navigation Links
Defensive measures: Toward a vaccine for Ebola
Date:12/5/2011

On August 26, 1976, a time bomb exploded in Yambuku, a remote village in Zaire, (now the Democratic Republic of the Congo). A threadlike virus known as Ebola had emerged, soon earning a grim distinction as one of the most lethal, naturally occurring pathogens on earth, killing up to 90 percent of its victims, and producing a terrifying constellation of symptoms known as hemorrhagic fever.

Now, Charles Arntzen, a researcher at the Biodesign Institute at Arizona State University, along with colleagues from ASU, the University of Arizona College of Medicine-Phoenix, and the United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, have made progress toward a vaccine against the deadly virus.

The group's research results appear in today's issue of the Proceedings of the National Academy of Science, along with a companion paper by their collaborators at Mapp Pharmaceuticals in San Diego, CA, led by Larry Zeitlin. Arntzen's group demonstrated that a plant-derived vaccine for Ebola provided strong immunological protection in a mouse model.

If early efforts bear fruit, an Ebola vaccine could be stockpiled for use in the United States, should the country fall victim to a natural outbreak or a bioterrorism event in which a weaponized strain of the virus were unleashed on soldiers or the public.

To date, Ebola outbreaks have been mercifully rare. For researchers like Arntzen however, this presents a challenge: "With other lethal viruses like HIV there is a common pattern of occurrence, allowing for vaccine testing. For example, an AIDS vaccine study is now underway at two locations in Thailand, which were chosen because of a current high incidence of the disease."

By contrast, Ebola events are fleeting, episodic and largely unpredictable. For this reason, Arntzen stresses that an Ebola vaccine would most likely not be used prophylacticallythat is, as a means of protecting large populations,
'/>"/>

Contact: Joseph Caspermeyer
Joseph.Caspermeyer@asu.edu
Arizona State University
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. Cells die so defensive organs can live
2. Rapid venom evolution in pit vipers may be defensive
3. Toward more cost-effective production of biofuels from plant lignocellulosic biomass
4. Leicester leads the way towards a sustainable lake in Africa
5. Advance toward a breath test to diagnose multiple sclerosis
6. Progress towards developing plants that accommodate climate change
7. Wildlife Conservation Society study uncovers a predictable sequence toward coral reef collapse
8. Award-winning research points toward Alzheimer’s vaccine
9. Another step toward resisting breast cancer
10. Toward new medications for chronic brain diseases
11. Toward a more efficient use of solar energy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Defensive measures: Toward a vaccine for Ebola  
(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
(Date:10/15/2014)... ,Models of Life, is a non-traditional biophysics textbook and ... book is a journey of discovery into biological systems ... and biological regulation. It is about how our genes ... between the billions of cells in an organism. It ... between principles, which can be found on both large ...
(Date:10/15/2014)... will be awarded the 44th Rosenstiel Award for Distinguished ... pioneering research exploring the mechanisms of genomic instability and ... Alt is the second alumnus to win the Rosenstiel ... in 2003. , Alt is the Charles A. Janeway ... Medical School and an investigator at the Howard Hughes ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... a medical doctor. Yet he is seen as a hero ... D.H. was diagnosed with terminal lung cancer. , "In 2000 ... few months to live," said Pardini, a professor of biochemistry ... the University of Nevada, Reno. "But five years later, ...
... for treating Parkinson's diseases and other neurodegenerative disorders is getting ... brain is a complex organ with many different types of ... barrier erected by blood vessels and glial cells -- the ... of most drugs from the bloodstream. , But now scientists ...
... of history students have discovered the antler of an Irish Elk ... , Although the exact age of the antler has yet to ... (Megaloceros giganteus) lived around 11,000 years ago. The giant deer roamed ... the end of the last Ice Age, as the glaciers retreated ...
Cached Biology News:The nude mouse tale: Omega-3 fats save the life of a terminal cancer patient 2Engineered Stem Cells Show Promise For Sneaking Drugs Into The Brain 2Engineered Stem Cells Show Promise For Sneaking Drugs Into The Brain 3Students discover 11,000 year old remains of Irish Elk 2
(Date:10/22/2014)... DUBLIN , Oct. 22, 2014 ... addition of the "Global DNA Diagnostics Market ... - Size, Share, Global Trends, Company Profiles, Demand, ... 2013 - 2020" report to their offering. ... diagnostics Market (products, applications, techniques, end users and ...
(Date:10/22/2014)... The North American crystal oscillator market report defines and ... forecast of revenue. This market was valued at $531.4 ... million by 2018, at a CAGR of 3.3% from ... the North American crystal oscillator market report, to get ... provides a glimpse of the segmentation of the market, ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 WriteResult, ... services – has been working with a team of ... New Haven Farms Community Farming Collaborative to provide electronic ... solution. The study, which started in May, aims ... that provides participants weekly exposure to and participation in ...
(Date:10/22/2014)... Physicians Choice Laboratory Services (PCLS) ... which enables healthcare providers to individualize therapeutic treatments ... results, healthcare providers are better able to assess ... minimizing risks for adverse drug reactions and interactions. ... FDA [1] more than 2.2 million adverse drug ...
Breaking Biology Technology:Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3
... ... of Bavituximab,s Mechanism of Action in ... - Results Further Support Future Clinical Trials Testing Bavituximab in ... Combination With Radiation Therapy -, TUSTIN, Calif., Sept. 4 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ...
... Sept. 4 Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) ... Alexion Pharmaceuticals, will present at the,Bear Stearns 20th Annual ... on Tuesday, September 11, 2007. An audio webcast ... can,access the webcast at: http://www.alexionpharm.com . An archived ...
... To Maintain Roles as Vice Chairman of The Foundry and Advisor ... ... Labs, MENLO PARK, Calif., Sept. 4 Morgenthaler ... and information technology investments, today announced the,addition of Hank Plain as ...
Cached Biology Technology:Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer 2Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer 3Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer 4Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer 5Hank Plain Joins Morgenthaler Ventures as Partner 2Hank Plain Joins Morgenthaler Ventures as Partner 3
rat Leptin...
...
... with the xPONENT Software Interface is ... assays using Upstate's Beadlyte® reagents. This ... friendly xPONENT software developed by Luminex. ... for commercial or home-made multiplex kits. ...
... L samples, featuring 24-position turntable. Provides up to 30 minutes of walkaway time. Automatic ... and record keeping. RS-232 port. ... ... ...
Biology Products: